CBC Radio: Injectable Peptides Called 'A Giant Scam' by Scientists
CBC investigation compares the peptide trend to historical pseudoscience, with scientists emphasizing no large-scale human trials exist for peptides sold by influencers.
#safety
8 stories
The Peptide Market Hits $50B — But Safety Questions Loom
The regulated peptide market is worth $50 billion and projected to double by the early 2030s. Unregulated peptides like BPC-157 and TB-500 lack rigorous human safety data and are increasingly sourced from gray-market Chinese distributors.
Study Links Semaglutide to Rare Skin Pain Condition
A new study identified a potential link between semaglutide use and a rare dermatological pain syndrome. Researchers also referenced Phase 2 retatrutide data as part of broader incretin safety analysis.
Experts Warn About Safety Risks of Unproven Peptides as FDA Reversal Looms
Eric Topol of Scripps Research called peptide data "woefully minuscule," warning about impurities, random dosing, and dangerous stacking of unproven compounds from gray-market sources.
AP Investigation: Unapproved Peptide Injections Promoted by Influencers
In-depth AP investigation on influencers and celebrities promoting unapproved injectable peptides produced by compounding pharmacies without FDA-level scrutiny.
GLP-1 Drugs May Pose Disproportionate Risks for EDS Patients
Clinical insights suggest GLP-1 agonists may pose extra risks for Ehlers-Danlos Syndrome patients, as delayed gastric emptying can exacerbate GI connective tissue vulnerabilities.
Skeptic Magazine: Peptide Deregulation Could Be 'Biggest Medical Experiment in History'
Physician William Meller describes treating a patient in anaphylaxis after self-injecting online peptides, and critiques RFK Jr.'s plan to move ~14 compounds off the FDA restricted list.
Men's Health UK: Men Injecting Peptides for Muscle and Recovery Face Real Risks
Investigation into men injecting BPC-157 and Thymosin Alpha-1 from unregulated internet suppliers. Doctors warn of severe allergic reactions and potential cancer risk from growth-pathway compounds.